

Alessandro Federico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2818681/publications.pdf>

Version: 2024-02-01

185
papers

7,836
citations

61984

43
h-index

56724

83
g-index

189
all docs

189
docs citations

189
times ranked

11281
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic inflammation and oxidative stress in human carcinogenesis. International Journal of Cancer, 2007, 121, 2381-2386.	5.1	809
2	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-14.	4.0	447
3	Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases. Journal of Clinical Gastroenterology, 2005, 39, 540-543.	2.2	406
4	Oxidative stress in viral and alcoholic hepatitis. Free Radical Biology and Medicine, 2003, 34, 1-10.	2.9	376
5	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, The, 2018, 391, 2417-2429.	13.7	345
6	Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules, 2017, 22, 191.	3.8	301
7	Non Alcoholic Fatty Liver: Epidemiology and Natural History. Reviews on Recent Clinical Trials, 2015, 9, 126-133.	0.8	215
8	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biology and Medicine, 2012, 52, 1658-1665.	2.9	201
9	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	3.7	193
10	Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology, 2013, 145, 121-128.e1.	1.3	177
11	Gut-liver axis: a new point of attack to treat chronic liver damage?. American Journal of Gastroenterology, 2002, 97, 2144-2146.	0.4	143
12	Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut, 2010, 59, 1465-1470.	12.1	132
13	DRINKING HABITS OF SUBJECTS WITH HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE: PREVALENCE AND EFFECT ON CLINICAL, VIROLOGICAL AND PATHOLOGICAL ASPECTS. Alcohol and Alcoholism, 2000, 35, 296-301.	1.6	108
14	The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study. Digestive Diseases and Sciences, 2007, 52, 2387-2395.	2.3	97
15	Postoperative Changes in Fecal Bacterial Communities and Fermentation Products in Obese Patients Undergoing Bilio-Intestinal Bypass. Frontiers in Microbiology, 2016, 7, 200.	3.5	94
16	<i>Helicobacter pylori</i> secondâ€line rescue therapy with levofloxacinâ€and bismuthâ€containing quadruple therapy, after failure of standard triple or nonâ€bismuth quadruple treatments. Alimentary Pharmacology and Therapeutics, 2015, 41, 768-775.	3.7	91
17	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. International Journal of Environmental Research and Public Health, 2019, 16, 3415.	2.6	90
18	Total parenteral nutrition-related gastroenterological complications. Digestive and Liver Disease, 2006, 38, 623-642.	0.9	87

#	ARTICLE	IF	CITATIONS
19	Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3011.	2.6	86
20	Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2012, 143, 55-61.e1.	1.3	81
21	Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. <i>European Journal of Clinical Nutrition</i> , 2001, 55, 293-297.	2.9	76
22	Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism†Multicentre prospective study by the “Nutritional Problems in Gastroenterology” Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2005, 37, 681-688.	0.9	76
23	Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. <i>Digestive and Liver Disease</i> , 2010, 42, 200-204.	0.9	76
24	Efficacy and safety of new direct antiviral agents in hepatitis C virus“infected patients with diffuse large B“cell non“Hodgkin's lymphoma. <i>Hepatology</i> , 2018, 67, 48-55.	7.3	76
25	Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. <i>Translational Research</i> , 2016, 167, 116-124.	5.0	73
26	A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. <i>Gut</i> , 2006, 55, 901-902.	12.1	72
27	<i>Helicobacter pylori</i> infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. <i>United European Gastroenterology Journal</i> , 2015, 3, 17-24.	3.8	72
28	Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 494.	4.1	70
29	Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. <i>International Journal of Food Sciences and Nutrition</i> , 2017, 68, 18-27.	2.8	69
30	Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-8.	4.0	66
31	Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, S218-S223.	2.2	65
32	Fat: A matter of disturbance for the immune system. <i>World Journal of Gastroenterology</i> , 2010, 16, 4762.	3.3	65
33	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018, 20, 721-733.	5.3	65
34	Trace Elements and Chronic Liver Diseases. <i>Journal of Trace Elements in Medicine and Biology</i> , 1997, 11, 158-161.	3.0	64
35	Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2004, 36, 398-405.	0.9	56
36	An Italian Survey on Dietary Habits and Changes during the COVID-19 Lockdown. <i>Nutrients</i> , 2021, 13, 1197.	4.1	54

#	ARTICLE	IF	CITATIONS
37	Epidemiology and Natural History of Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 167-174.	0.8	52
38	Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Alimentary Pharmacology and Therapeutics, 2018, 47, 826-837.	3.7	51
39	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. Nutrients, 2021, 13, 933.	4.1	50
40	Herbal Products: Benefits, Limits, and Applications in Chronic Liver Disease. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-19.	1.2	49
41	Relationship of Blood Trace Elements to Liver Damage, Nutritional Status, and Oxidative Stress in Chronic Nonalcoholic Liver Disease. Biological Trace Element Research, 2001, 81, 245-254.	3.5	47
42	Gastrointestinal Hormones, Intestinal Microbiota and Metabolic Homeostasis in Obese Patients: Effect of Bariatric Surgery. In Vivo, 2016, 30, 321-30.	1.3	47
43	Extra-Gastric Manifestations of Helicobacter pylori Infection. Journal of Clinical Medicine, 2020, 9, 3887.	2.4	46
44	Non-alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterology, 2017, 17, 35.	2.0	45
45	The Role of Stress in Inflammatory Bowel Diseases. Current Pharmaceutical Design, 2017, 23, 3997-4002.	1.9	45
46	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-12.	4.0	43
47	The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. European Review for Medical and Pharmacological Sciences, 2016, 20, 4731-4741.	0.7	43
48	Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. International Journal of Molecular Sciences, 2021, 22, 436.	4.1	40
49	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health, 2019, 16, 3134.	2.6	39
50	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	3.7	38
51	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	3.7	38
52	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics, 2021, 17, 12.	3.0	37
53	A case of hepatotoxicity caused by green tea. Free Radical Biology and Medicine, 2007, 43, 474-474.	2.9	36
54	Eradication of Helicobacter pylori infection: Which regimen first?. World Journal of Gastroenterology, 2014, 20, 665.	3.3	36

#	ARTICLE	IF	CITATIONS
55	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 16841.	3.3	36
56	Ameliorative effect of Silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures. <i>Scientific Reports</i> , 2019, 9, 3228.	3.3	34
57	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	4.1	34
58	Gut microbiota, obesity and metabolic disorders. <i>Minerva Gastroenterology</i> , 2017, 63, 337-344.	0.5	34
59	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. <i>Antiviral Therapy</i> , 2018, 23, 129-138.	1.0	33
60	Forecasting Hepatitis C liver disease burden on real-life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
61	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 120-137.	0.9	32
62	Oral Microbiota and Salivary Levels of Oral Pathogens in Gastro-Intestinal Diseases: Current Knowledge and Exploratory Study. <i>Microorganisms</i> , 2021, 9, 1064.	3.6	32
63	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	3.9	31
64	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 159-166.	0.8	30
65	Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. <i>United European Gastroenterology Journal</i> , 2014, 2, 279-287.	3.8	29
66	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2020, 52, 374-391.	0.9	29
67	Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives. <i>Digestive and Liver Disease</i> , 2006, 38, 789-801.	0.9	28
68	Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage?. <i>Liver International</i> , 2013, 33, 687-697.	3.9	28
69	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	4.0	28
70	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2755.	2.6	28
71	Alteration of haemostasis in non-metastatic gastric cancer. <i>Digestive and Liver Disease</i> , 2001, 33, 546-550.	0.9	27
72	Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. <i>United European Gastroenterology Journal</i> , 2017, 5, 37-44.	3.8	27

#	ARTICLE	IF	CITATIONS
73	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 68305-68316.	1.8	27
74	Gut-Brain Axis in Gastric Mucosal Damage and Protection. <i>Current Neuropharmacology</i> , 2016, 14, 959-966.	2.9	27
75	Gut microbiota and the liver. <i>Minerva Gastroenterology</i> , 2017, 63, 385-398.	0.5	27
76	Emerging drugs for non-alcoholic fatty liver disease. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 145-158.	2.4	26
77	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. <i>Oncology Letters</i> , 2015, 9, 1628-1632.	1.8	25
78	Pharmacotherapy of alcoholic liver disease in clinical practice. <i>International Journal of Clinical Practice</i> , 2016, 70, 119-131.	1.7	24
79	Human exposure to Bisphenol A and liver health status: Quantification of urinary and circulating levels by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 140, 105-112.	2.8	24
80	Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	5.1	24
81	Urotensin II receptor is overexpressed in colon cancer cell lines and in colon carcinoma in humans. <i>European Journal of Clinical Investigation</i> , 2014, 44, 285-294.	3.4	22
82	Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015, 47, 108-113.	0.9	22
83	New silibinin glyco-conjugates: Synthesis and evaluation of antioxidant properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5147-5149.	2.2	21
84	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334.	2.6	21
85	Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. <i>Nutrients</i> , 2020, 12, 928.	4.1	21
86	Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2190.	4.1	20
87	Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. <i>Helicobacter</i> , 2020, 25, e12694.	3.5	20
88	Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 261-268.	0.9	20
89	The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. <i>European Review for Medical and Pharmacological Sciences</i> , 2009, 13, 285-93.	0.7	19
90	The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. <i>Journal of Clinical Medicine</i> , 2022, 11, 3649.	2.4	19

#	ARTICLE	IF	CITATIONS
91	Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2017, 9, 1074.	4.1	18
92	Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. <i>In Vivo</i> , 2015, 29, 569-75.	1.3	18
93	Heat shock protein 27 expression in patients with chronic liver damage. <i>Immunobiology</i> , 2005, 209, 729-735.	1.9	17
94	The Impact of Diet on Liver Fibrosis and on Response to Interferon Therapy in Patients With HCV-Related Chronic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 3159-3166.	0.4	17
95	Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. <i>Current Cancer Drug Targets</i> , 2017, 17, 109-121.	1.6	17
96	The Lesson from the First Italian Lockdown: Impacts on Anxiety and Depressive Symptoms and Sleep Quality in Patients with Remission of Inflammatory Bowel Disease. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 109-119.	0.8	17
97	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3369.	2.6	16
98	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
99	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021, 75, 1355-1366.	3.7	15
100	The treatment of NAFLD. <i>European Review for Medical and Pharmacological Sciences</i> , 2005, 9, 299-304.	0.7	15
101	Peptide Hp(2â€“20) accelerates healing of TNBSâ€“induced colitis in the rat. <i>United European Gastroenterology Journal</i> , 2018, 6, 1428-1436.	3.8	14
102	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. <i>Nutrients</i> , 2021, 13, 1679.	4.1	14
103	Drinking habits and risk of altered liver enzymes in the general population of a rural area in Southern Italy. <i>Digestive and Liver Disease</i> , 2007, 39, 748-752.	0.9	13
104	Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer. <i>Medical Oncology</i> , 2021, 38, 13.	2.5	13
105	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. <i>In Vivo</i> , 2017, 31, 609-618.	1.3	13
106	Ultrasound-guided percutaneous biopsy for diagnosis of gastrointestinal lesions. <i>Digestive and Liver Disease</i> , 2013, 45, 816-819.	0.9	12
107	Pegylated interferon Î± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014, 46, 826-832.	0.9	12
108	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. <i>Antiviral Therapy</i> , 2017, 22, 551-558.	1.0	12

#	ARTICLE	IF	CITATIONS
109	Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study. <i>In Vivo</i> , 2015, 29, 405-8.	1.3	11
110	Coeliac disease and C virus-related chronic hepatitis: a non association. <i>BMC Research Notes</i> , 2012, 5, 533.	1.4	10
111	Crohn's disease and skin. <i>United European Gastroenterology Journal</i> , 2016, 4, 165-171.	3.8	10
112	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 734847.	2.6	10
113	The effects of alcohol on gastrointestinal tract, liver and pancreas: evidence-based suggestions for clinical management. <i>European Review for Medical and Pharmacological Sciences</i> , 2015, 19, 1922-40.	0.7	10
114	Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the "ANSWER" study. <i>Journal of Hepatology</i> , 2017, 66, S93.	3.7	9
115	Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: <i>In vivo</i> and <i>in vitro</i> studies. <i>World Journal of Gastroenterology</i> , 2007, 13, 3677.	3.3	9
116	The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett's esophagus after medical and surgical treatment: a prospective case-control study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 648-657.	2.4	8
117	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
118	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , 2021, 13, 3810.	3.7	8
119	Can dietary intake influence plasma levels of amino acids in liver cirrhosis?. <i>Digestive and Liver Disease</i> , 2000, 32, 611-616.	0.9	7
120	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. <i>Annals of Hepatology</i> , 2015, 14, 420-424.	1.5	7
121	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	3.7	7
122	Alcoholic Liver Disease and Hepatitis C Chronic Infection. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 201-207.	0.8	7
123	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. <i>Hepatitis Monthly</i> , 2015, 15, e18640.	0.2	7
124	A pilot study on the ability of clinoptilolite to absorb ethanol <i>in vivo</i> in healthy drinkers: effect of gender. <i>Journal of Physiology and Pharmacology</i> , 2015, 66, 441-7.	1.1	7
125	Humerus Metastasis From Cholangiocarcinoma: A Case Report. <i>Gastroenterology Research</i> , 2013, 6, 39-41.	1.3	6
126	Critical review on the use and abuse of alcohol. When the dose makes the difference. <i>Minerva Medica</i> , 2020, 111, 344-353.	0.9	6

#	ARTICLE	IF	CITATIONS
127	Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis. <i>Hepatitis Monthly</i> , 2014, 14, e16632.	0.2	6
128	Hashimoto's Thyroiditis and Entero-Chromaffin-like Cell Hyperplasia: Early Detection and Somatostatin Analogue Treatment. <i>European Journal of Inflammation</i> , 2013, 11, 863-870.	0.5	5
129	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. <i>Digestive and Liver Disease</i> , 2017, 49, 197-201.	0.9	5
130	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. <i>Antiviral Therapy</i> , 2019, 24, 485-493.	1.0	5
131	Liver fibrosis: which are independent predictors?. <i>Minerva Medica</i> , 2019, 110, 183-184.	0.9	5
132	The analysis of alcohol consumption during the severe acute respiratory syndrome Coronavirus 2 Italian lockdown. <i>Minerva Medica</i> , 2023, 113, .	0.9	5
133	Management and outcomes of hepatic cirrhosis: Findings from the RING study. <i>Hepatology Research</i> , 2006, 36, 176-181.	3.4	4
134	Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana) Tj ETQq0 0 0 rgBT /Overlock 10 Tf S618-S619.	3.7	4
135	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 164-177.	0.8	4
136	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 306-316.	0.8	4
137	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. <i>Annals of Hepatology</i> , 2015, 14, 420-4.	1.5	4
138	Evaluation of the Efficacy and Safety of a Compound of Micronized Flavonoids in Combination With Vitamin C and Extracts of <i>Centella asiatica</i> , <i>Vaccinium myrtillus</i> , and <i>Vitis vinifera</i> for the Reduction of Hemorrhoidal Symptoms in Patients With Grade II and III Hemorrhoidal Disease: A Retrospective Real-Life Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 773320.	3.5	4
139	Just Drink a Glass of Water? Effects of Bicarbonate" Sulfate" Calcium" Magnesium Water on the Gut" Liver Axis. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
140	Endoscopic diagnosis of secondary rectal teratoma in a young woman with constipation and positive fecal occult blood test. <i>Endoscopy</i> , 2010, 42, E254-E255.	1.8	3
141	825 Silybin conjugated with phosphatidylcholine and vitamin E improves liver damage in patients with NAFLD: The results of a randomized multicentre double-blind vs placebo trial. <i>Journal of Hepatology</i> , 2011, 54, S330-S331.	3.7	3
142	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. <i>Digestive and Liver Disease</i> , 2015, 47, e6.	0.9	3
143	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 23-28.	2.2	3
144	Secondary Extramedullary Plasmacytoma of the Duodenum: An Unusual Endoscopic Presentation. <i>Gastroenterology Research</i> , 2013, 6, 110-111.	1.3	3

#	ARTICLE	IF	CITATIONS
145	Five-Day Quadruple Concomitant Therapy vs Ten-Day Sequential Therapy for Eradication of H. pylori Infection. <i>Gastroenterology</i> , 2011, 140, S-148-S-149.	1.3	2
146	May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report. <i>BMC Gastroenterology</i> , 2021, 21, 31.	2.0	2
147	Does polychemotherapy with 5-fluorouracil, methotrexate, and L-folinic acid influence the selenium, zinc, and copper serum levels in cancer of digestive tract?. <i>Journal of Trace Elements in Experimental Medicine</i> , 2001, 14, 73-79.	0.8	1
148	P.14.5 THE ROLE OF HELICOBACTER PYLORI INFECTION AND SMALL INTESTINAL BACTERIAL OVERGROWTH IN ROSACEA. <i>Digestive and Liver Disease</i> , 2014, 46, S110.	0.9	1
149	P.10.2 EFFECTS OF SILYBIN ADMINISTRATION ON THE REDOX STATE AND OXIDATIVE STRESS RESPONSE OF HUMAN ENDOTHELIAL CELLS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS. <i>Digestive and Liver Disease</i> , 2016, 48, e178.	0.9	1
150	P.09.8: Role of Bisphenol a as Environmental Factor in the Promotion of Non-Alcoholic Fatty Liver Disease: In VITRO and in VIVO Protective Effects of Silybin. <i>Digestive and Liver Disease</i> , 2017, 49, e190.	0.9	1
151	Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo Tj ETQq1 1 0.784314 rgBT /Over	3.7	1
152	P.08.8: Silybin in Combination with Regorafenib as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer Patients. <i>Digestive and Liver Disease</i> , 2017, 49, e181-e182.	0.9	1
153	A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2018, In Press, .	0.2	1
154	Increased nitric oxide production as evaluated by nitrosogluthathione levels in patients with chronic liver disease and alcohol abuse. <i>Gastroenterology</i> , 2000, 118, A926.	1.3	0
155	P.28 LEVOFLOXACIN-BASED SEQUENTIAL THERAPY VS CLARITHROMYCIN-BASED SEQUENTIAL THERAPY FOR ERADICATION OF H. PYLORI INFECTION. <i>Digestive and Liver Disease</i> , 2010, 42, S112-S113.	0.9	0
156	P.124 A PROBIOTIC TREATMENT AMELIORATES CCL4-INDUCED LIVER FIBROSIS IN RATS. <i>Digestive and Liver Disease</i> , 2010, 42, S147.	0.9	0
157	P.239 FOOD CHOICE AND GASTROINTESTINAL HORMONES IN CHRONIC LIVER DISEASES. <i>Digestive and Liver Disease</i> , 2010, 42, S185.	0.9	0
158	F-49 A randomized multicentre double-blind vs placebo trial: Evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, S108.	0.9	0
159	P.1.123: LEVOFLOXACIN-CONTAINING QUADRUPLE CONCOMITANT THERAPY FOR ERADICATION OF H PYLORI INFECTION. <i>Digestive and Liver Disease</i> , 2011, 43, S188-S189.	0.9	0
160	993 ALCOHOL CONSUMPTION AMONG ITALIAN YOUNG PEOPLE. A NEW MODALITY OF INTERVIEW: FACEBOOK. <i>Journal of Hepatology</i> , 2012, 56, S388.	3.7	0
161	1252 EFFECT OF BARIATRIC SURGERY ON SERUM LEVELS OF GASTROINTESTINAL HORMONES IN OBESE NAFLD PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S507.	3.7	0
162	P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY. <i>Digestive and Liver Disease</i> , 2014, 46, S123.	0.9	0

#	ARTICLE	IF	CITATIONS
163	P070 Healing of TNBS-induced colitis in the rat by peptide Hp(2-20). Journal of Crohn's and Colitis, 2014, 8, S91-S92.	1.3	0
164	No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy. Digestive and Liver Disease, 2014, 46, e134-e135.	0.9	0
165	P.17.17 SERUM CONCENTRATION OF 49 PROTEINS IN PATIENTS WITH CHRONIC GASTRITIS BY MULTIPLEX BIOMETRIC IMMUNOASSAY. Digestive and Liver Disease, 2014, 46, S126.	0.9	0
166	P.16.18 OPTIMIZED CONTRAST-ENHANCED ULTRASONOGRAPHY FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN CIRRHOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY. Digestive and Liver Disease, 2014, 46, S120.	0.9	0
167	P.06.24 GENDER DIFFERENCE IN DERMATOLOGICAL ADVERSE EFFECTS DURING ANTIBODIES ANTI-TNF ALFA THERAPY IN CHRONIC INFLAMMATORY BOWEL DISEASE. Digestive and Liver Disease, 2014, 46, S78.	0.9	0
168	ENOS dysfunction in Steatosis and Steatohepatitis. Digestive and Liver Disease, 2015, 47, e55.	0.9	0
169	P.01.4 ENDOCAN AS SERUM MARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND/OR TYPE 2 DIABETES. Digestive and Liver Disease, 2016, 48, e131.	0.9	0
170	Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study. Digestive and Liver Disease, 2016, 48, e234.	0.9	0
171	P.04.6 PREVALENCE OF H. PYLORI INFECTION IN SEXUAL PARTNERS OF H. PYLORI INFECTED SUBJECTS: ROLE OF GASTROESOPHAGEAL REFLUX. Digestive and Liver Disease, 2016, 48, e145.	0.9	0
172	P.10.1 REACTIVATION OF HEPATITIS B VIRUS IN CANCER PATIENTS TREATED WITH CHEMOTHERAPY FOR SOLID TUMORS. IS THE PROPHYLAXIS REALLY REQUIRED?. Digestive and Liver Disease, 2016, 48, e177.	0.9	0
173	Hospital dismissal data sheets on alcoholic liver diseases into three first aid divisions: A southern Italy survey. Digestive and Liver Disease, 2017, 49, e237-e238.	0.9	0
174	OC.08.6: Prevalence of Ultrasonographic Enthesitis in Patients with Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, e98-e99.	0.9	0
175	Forecasting liver disease burden. Digestive and Liver Disease, 2018, 50, 10-11.	0.9	0
176	Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the "underwater portion of the iceberg" matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?. Journal of Hepatology, 2018, 68, S149-S150.	3.7	0
177	P.04.5 EFFECT OF BISPHENOL A EXPOSURE ON HEP-G2 CELLS AND ITS INTERFERENCE IN CELL PROLIFERATION, OXIDATIVE STRESS AND OXIDATIVE METABOLISM OF STEROID HORMONES. Digestive and Liver Disease, 2019, 51, e172-e173.	0.9	0
178	P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION. Digestive and Liver Disease, 2019, 51, e231.	0.9	0
179	Role of Bisphenol A on cell biology: effect on proliferation, oxidative stress and steroid hormones metabolism of HepG2 cells. Digestive and Liver Disease, 2019, 51, e46.	0.9	0
180	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
181	Oxidative Stress in Alcoholic Liver Disease: Clinical Studies. , 2005, , 775-783.		0
182	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 824879.	3.5	0
183	Colonic angiodysplasia with adenomatous epithelial foci. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2011, 20, 347.	0.9	0
184	Amelanotic metastatic melanoma of the stomach presenting with iron deficiency anemia. <i>Acta Gastro-Enterologica Belgica</i> , 2017, 80, 327-328.	1.0	0
185	Anorectal Function with High-Resolution Anorectal Manometry in Active Ulcerative Colitis and after Remission: A Pilot Study. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 97-102.	0.8	0